Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance.
BACKGROUND
Severely opioid-dependent patients are at high risk of both acquiring and spreading the hepatitis C virus (HCV). It is uncertain, however, whether these patients are possible candidates for HCV treatment. We therefore explored treatment retention and adherence as well as sustained viral response in co-morbid severely opioid-dependent subjects under heroin maintenance, who previously failed in conventional substitution treatment or were not in any drug treatment.


METHODS
All patients in heroin maintenance in the German heroin trial, who received standard antiviral HCV therapy with pegylated interferon and ribavirin, were included. Co-consumption of licit and illicit drugs was tolerated as long as it did not interfere with treatment.


RESULTS
Twenty-six patients in heroin maintenance were treated for chronic HCV infection. Both the Global Severity Index of the Symptom Checklist 90-R (average score 65.9) and the Opiate Treatment Index (average score 16.6) indicated relevant co-morbidity. Twenty-one patients (81%) were retained in treatment; the adherence rate was 92%. Eighteen patients (69%) achieved a sustained viral response, with a 100% response rate for genotype 2, 90% for genotype 3, and 42% for genotype 1.


CONCLUSIONS
This is the first study that investigates the feasibility of antiviral HCV treatment in a well-defined sample of co-morbid severely opioid-dependent subjects in heroin maintenance treatment. Viral response rates are comparable to non-drug-user populations. Within a need-adapted treatment setting, HCV treatment may even be extended to difficult-to-treat opioid-dependent patients.
Schulte
Bernd
B
Centre for Interdisciplinary Addiction Research, Hamburg University, University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany; Institute for Therapy Research, Parzivalstrasse 25, 80804 Munich, Germany.
Schütt
Sabine
S
Brack
Jochen
J
Isernhagen
Konrad
K
Deibler
Peter
P
Dilg
Christoph
C
Verthein
Uwe
U
Haasen
Christian
C
Reimer
Jens
J
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D005838:Genotype; D005858:Germany; D006304:Health Status; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D003932:Heroin / Q000627:therapeutic use*; D006556:Heroin Dependence / Q000150:complications* / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008297:Male; D008603:Mental Health; D008875:Middle Aged; D009294:Narcotics / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use; D016320:Substance Abuse Treatment Centers; D015819:Substance Abuse, Intravenous; D019562:Viral Load; D055815:Young Adult
D000998:Antiviral Agents; D009294:Narcotics; D012254:Ribavirin; D003932:Heroin; D007372:Interferons